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Abstract
Under physiological conditions, transferrin receptor 2 (TfR2) is expressed in the liver and its balance is related to the
cell cycle rather than to intracellular iron levels. We recently showed that TfR2 is highly expressed in glioblastoma cell
lines. Here, we demonstrate that, in these cells, TfR2 appears to localize in lipid rafts, induces extracellular signal–
regulated kinase 1/2 phosphorylation after transferrin binding, and contributes to cell proliferation, as shown by
RNA silencing experiments. In vitro hypoxic conditions induce a significant TfR2 up-regulation, suggesting a role in
tumor angiogenesis. As assessed by immunohistochemistry, the level of TfR2 expression in astrocytic tumors is re-
lated to histologic grade, with the highest expression observed in glioblastomas. The level of TfR2 expression repre-
sents a favorable prognostic factor, which is associated with the higher sensitivity to temozolomide of TfR2-positive
tumor cells in vitro. The endothelial cells of glioblastoma vasculature also stain for TfR2, whereas those of the normal
brain vessels donot. Importantly, TfR2 is expressedby thesubpopulationof glioblastomacellswith propertiesof cancer-
initiating cells. TfR2-positive glioblastoma cells retain their TfR2 expression on xenografting in immunodeficient mice.
In conclusion, our observations demonstrate that TfR2 is a neoantigen for astrocytomas that seems attractive for de-
veloping target therapies.
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Introduction
Cellular iron uptake is mediated by a ubiquitously expressed receptor
for transferrin (Tf), called transferrin receptor 1 (TfR1) [1]. TfR1 plays
a key role in the control of the rate of cellular iron uptake, tuning the
amount of iron delivered to the cells to the metabolic needs.
In 1999, Kawabata et al. [2] cloned a second TfR-like molecule
known as the transferrin receptor 2 (TfR2). Differently from TfR1,
TfR2 is not regulated by intracellular iron levels and it seems to be regu-
lated in accordance with the cell cycle [3,4]. Major differences between
TfR1 and TfR2 concern their expression patterns. TfR1 is expressed on
all cells, except mature erythrocytes and terminally differentiated cells,
whereas human TfR2 messenger RNA (mRNA) is highly expressed in
the liver and, to a lesser extent, in erythroid cells, spleen, lung, muscle,
prostate, and peripheral mononuclear cells [2,3]. Furthermore, muta-
tions of the TfR2 gene produce hemochromatosis type 3, with signifi-
cant hepatic iron loading [5,6], and TfR2-deficient mice show a
phenotype of parenchymal iron overload and features of human TfR2-
related hemochromatosis [6]. These observations clearly indicate that
TfR2 has a unique, yet unknown role in the regulation of iron homeo-
stasis rather than a simple contribution to cellular iron uptake. This con-
clusion is reinforced by a recent study showing that TfR2, at variance
with TfR1, is localized in lipid rafts, peculiar cell membrane domains
involved in the generation of receptor-mediated cell signaling [7]. In a
recent study, we explored TfR2 expression in a panel of cancer cell lines,
including glioblastomas (GBMs), and we observed that approximately
40% of these cell lines express TfR2 [8].
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GBM is the most malignant and, unfortunately, the most common
brain tumor: its incidence is approximately 5 cases per 100,000 people
[9]. Although molecular markers for GBM have helped identify pa-
tients responsive to current therapies [10], the overall survival of re-
sponsive patients has not substantially changed in the last 20 years [11].
The expression of TfR1 has been explored in normal brain and in
brain tumors. In normal brain, TfR1 was detected primarily in endo-
thelial cells. Among brain tumors, astrocytomas clearly express TfR1,
with GBM showing the highest expression [12]. As in other neoplasms,
TfR1 in gliomas induces increased intracellular iron accumulation [13]
and promotes tumor progression by two mechanisms, namely an in-
crease in proliferation rate and glutamate production [14], the latter
mechanism providing space for the progressing tumor mass [15]. Ac-
cordingly, it was suggested that TfR1 might be an appropriate target for
ligand-directed brain tumor immunotherapy. To this purpose, Tf-toxin
(Pseudomonas exotoxin A or diphtheria toxin mutant CRM107) conju-
gates were constructed and a strong cytotoxic effect on GBM cells was
demonstrated in vitro [16]. Regional therapy for recurrent malignant
brain tumors with Tf-CRM107 conjugate has also been tested in a small
series of GBM patients by interstitial microinfusion with encouraging
results [16]. In a phase 2 trial, Tf-CRM107 resulted in a 35% response
rate [17]. However, curative doses induced peritumoral brain toxicity,
consisting of thrombosed cortical vessels, which were explained by the
presence of TfR1 on endothelial cells.
In the present study, we first explored TfR2 expression in human
GBM cell lines and found that TfR2 appears to localize in lipid rafts
and that its activation, after binding with Tf, induces extracellular
signal–regulated kinase 1/2 (ERK 1/2) phosphorylation. TfR2 silencing
reduces GBM cell proliferation. Then, we assessed TfR2 expression
in human astrocytomas of various histologic grades. Interestingly, we
found that TfR2 is frequently and highly expressed in anaplastic astro-
cytomas (AA) and in GBM, with absent or very weak expression on
the endothelial cells of normal brain. Furthermore, we show that TfR2-
positive GBM cell lines, including one GBM stem cell line, maintain
TfR2 expression on xenografting in immunodeficient mice. These results
candidate TfR2 for target therapies of GBM tumors.
Materials and Methods
Antibodies
Anti-TfR2 monoclonal antibodies (mAbs, clones G/14C2 and
G/14E8) have been described in a previous study [18]. Anti-human
TfR1 used for Western blot analysis was from Zymed Laboratories
(South San Francisco, CA). Fluorescein isothiocyanate–conjugated
antihuman TfR1 used for flow cytometry analysis was from Becton
Dickinson (San Jose, CA). Anti–caveolin-1 (N-20) was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti–phospho-ERK1/
ERK2 (T202/Y204), anti–human/mouse/rat ERK1/ERK2, and anti–
human/mouse/rat hypoxia-inducible factor 1α (HIF-1α) were from
R&D Systems (Minneapolis, MN).
Cell Lines
Human GBM cell lines TB10, U87MG, T98G, and U251 were
grown in Dulbecco’s modified Eagle medium (DMEM; Gibco, Invitro-
gen, Milan, Italy) containing 10% fetal calf serum (Euroclone, Milan,
Italy). The human GBM stem cell lines BTSC1 and BTSC83 were also
used (these cell lines were coded as 1 and 7, respectively, in Ricci-Vitiani
et al. [19]).
Cell Treatments
To mimic hypoxia, GBM cell lines were incubated for either 24 or
48 hours in the presence of CoCl2 (100 μM; Sigma Co, St Louis, MO)
or under reduced oxygen tension (5% and 1%O2) and then analyzed for
TfR1 and TfR2 expression. In other experiments, GBM cells were in-
cubated in the presence of the MEK1 inhibitor PD184352 (Calbiochem,
San Diego, CA) added at the final concentrations of either 1 or 2 μM.
In some experiments, GBMcell lines have been incubated with temo-
zolomide (from 25 to 300 μM) and then, at various days after drug
addition, analyzed for the number of living cells and the cell cycle status.
In stimulation experiments, serum-starved GBM cells lines have
been treated for various times with DMEMcontaining 30 μMholo-Tf.
Flow Cytometry Analysis
Aliquots of nonadherent cells were harvested from the flask cultures
and processed as reported later. Adherent cells were detached from the tis-
sue culture flasks using a nonenzymatic detaching solution (Sigma). Cell
aliquots were washed twice in cold PBS and then incubated in the presence
of 1 μg/ml anti-TfR2 mAb (G/14E8) or 1 μg/ml irrelevant mouse im-
munoglobulin G (IgG) for 30 minutes at 4°C, washed twice in cold
PBS, and then incubated with affinity-purified phycoerythrin-labeled goat
antimouse IgGs diluted 1:40 (Dakopatts, Copenhagen, Denmark). After
two additional washes in PBS, the cells were analyzed in a FACS Scan flow
cytometer (Becton Dickinson). For TfR1 labeling, the cells were incu-
bated with phycoerythrin-conjugated anti-TfR1 Ab (Becton Dickinson).
Western Blot Analysis
Cellular lysates were resolved by 7.5% SDS-PAGE under reducing
and denaturing conditions and transferred to nitrocellulose filter. The
blots were blocked using 5% nonfat dry milk in TBST (10 mM Tris-
HCl pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 1 hour at room
temperature, followed by incubation with primary antibodies. After
washing with TBST, the filters were incubated with appropriate horse-
radish peroxidase–conjugated secondary antibodies (Bio-Rad, Hercules,
CA) for 1 hour at room temperature. Immunoreactivity was revealed by
using an ECL detection kit (Pierce, Rockford, IL).
Cell Cycle Analysis by Propidium Iodide/Fluorescence-
Activated Cell Sorting
Cells were harvested, washed, fixed, and resuspended in 400 μl of
propidium iodide solution (50 μg/ml propidium iodide, 0.1% Triton
X-100, and 0.1% sodium citrate in PBS; Cycle Plus DNA Staining
Kit; Becton Dickinson). The cells were then analyzed by flow cytome-
try using a software dedicated for DNA analysis (ModFit LT Software;
Verity Software House, Topsham, ME).
Confocal Microscopy Analysis
TB10 and U251 cells were plated on coverslips and left to adhere
overnight. Coverslips were stained with mouse mAbs directed against
TfR2 (15 minutes at 37°C), followed by a Texas Red–conjugated goat
antimouse IgG ( Jackson Immunoresearch,West Grove, PA). Cells were
then fixed and permeabilized (4%paraformaldehyde/2% sucrose, 10min-
utes at room temperature, plus 0.1% saponin, 30 minutes at room
temperature), saturated (1% normal goat serum), and stained with
a rabbit polyclonal anti–caveolin-1 (BD Bioscience, Bedford, MA),
followed by anAlexa 488–conjugated antirabbit IgG ( Jackson Immuno-
research). All images were acquired using an Olympus 1x70 (FV300
System) confocal microscope and processed with the Analysis software
(Olympus Life Sciences, Milan, Italy).
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Knockdown of TfR2 Using Small Interfering RNA
TfR2+ cells at 30% to 50% confluency were transfected overnight
with 20, 40, or 60 nM human TfR2 SMART pool (Dharmacon,
Lafayette, CO) or Stealth-negative control small interfering RNA
(siRNA; Invitrogen) using Oligofectamine (Invitrogen). After trans-
fection, the medium was replaced with DMEM containing 5% fetal
calf serum and incubated for a further 48 hours before assay. Levels
of TfR2 protein were determined by flow cytometry and Western
blot analysis. Statistical differences in TfR2 expression were deter-
mined using one-way analysis of variance and Bonferroni tests.
In some experiments, after transfection with control siRNA (40 nM)
or TfR2 siRNA (60 nM), U251 cells were treated for 72 hours with
temozolomide 300 μM and analyzed for the number of living cells
and the cell cycle status.
Isolation of Caveolae-Enriched Membrane Fractions
Caveolae-enriched membrane fractions were isolated according to
standard protocols [20,21]. Briefly, cell pellet was dissolved in 0.75 ml
of 2(N -morpholino)ethanesulfonic acid-buffered saline (25 mM 2(N -
morpholino)ethanesulfonic acid/pH 6.5, 150 mM NaCl) containing
1% Triton X-100 at 4°C. Cell lysate was Dounce-homogenized, ad-
justed to 40% sucrose, and placed at the bottom of an ultracentrifuge
tube. A 5% to 30% linear sucrose gradient was then placed above
the homogenate, and the mixture was centrifuged at 45,000 rpm for
16 hours at 4°C in a SW60 rotor (Beckman Instruments, Palo Alto,
CA). The caveolar fractions are visible as a light scattering band migrat-
ing at approximately 20% sucrose. Twelve 0.375-ml fractions were
collected from the top to the bottom of the gradient, separated by
SDS-PAGE and subjected to immunoblot analysis. Fractions 1 and 2
generally do not contain proteins, and thus, they were not subjected
to SDS-PAGE. Fraction 12 represents the nuclear portion.
Patients and Tumor Tissue Samples
This study included 81 adult patients who underwent craniotomy
for tumor resection at the Institute ofNeurosurgery, Catholic University
School ofMedicine, Rome, Italy, and were confirmed to have low-grade
astrocytoma (LGA; 24 patients), AA (22 patients), and GBM (35 pa-
tients) in the supratentorial compartment. Patients of pediatric age
were not included. All the patients provided written informed consent
according to research proposals approved by the ethical committee of the
Catholic University School of Medicine.
Brain tissue samples, which were adjacent to the tumor that had been
resected by radical excision, were also studied. Tumors located in the optic
nerve, hypothalamus, thalamus, suprasellar region, or posterior fossa were
excluded. There were 47 male and 34 female patients. The age of the pa-
tients ranged from 22 to 76 years; the mean age at surgery was 47.5 years.
No patient had received radiation therapy before surgery. The tumors were
diagnosed according to the classification of Burger and Scheithauer [22].
The postsurgical treatment plan included radiotherapy to limited
fields (2 Gy per fraction, once a day, 5 days a week, 60 Gy total dose)
and concomitant temozolamide (75 mg/m2 of body surface area per
day) for 7 days a week from the first to the last day of radiotherapy,
followed by five cycles of adjuvant temozolamide (at 200mg/m2 of body
surface area o days 1 to 5) given at 4-week intervals. Survival was calcu-
lated from the date of diagnosis.
Immunohistochemistry for TfR2
The anti-TfR2 mouse monoclonal antibody (1:150; clone G/14C2)
was used. The antigen was retrieved by microwave oven processing
(two cycles of 5 minutes, 500 W) in citrate buffer and the bound anti-
body was visualized with the avidin-biotin complex peroxidase method
(ABC ELITE Detection System; Vector, Burlingame, CA). Hydrogen
peroxide, normal goat blocking serum, biotinylated immunoglobulins,
avidin-biotin complexes, and 3-amino-9-ethyl-ethylcarbazole substrate
solutions were used according to themanufacturer. Sections were lightly
counterstained with hematoxylin for 25 seconds and mounted in Per-
mount Slide Mounting Fluid (The Science Co, Denver, CO). The in-
tensity of staining for TfR2 in the tumor tissue sections was graded on
a scale from 0 to 3+, with 0 indicating no detectable staining, 1+ slight
staining of the cytoplasm only discernible in 400× high-power field, 2+
moderate staining of the cytoplasm outlining the cellular details clearly
detectable in 100× to 200× field, and 3+ intense staining of all the cyto-
plasm that obscures the nucleus detectable in 20× field. The percentage
of TfR2-positive cells was determined with respect to the total number of
cells in high-power fields (400×). In each case, more than 1500 cells were
counted in randomly selected nonsuperimposing areas of the tumor,
which were devoid of massive necrosis. The percentage of TfR2-positive
cells was evaluated independently by two observers (F.P. and L.M.L.) who
were unaware of the clinical data.Differences between the extreme counts
of the two observers never exceeded 5%. Interobserver agreement was
reached in the first analysis in 90% of cases; for the remaining cases, a
consensus was reached by a joint review of the slides.
Tumor Xenografts in Immunodeficient Mice
Four-week-old male nude mice (Harlan, Udine, Italy) were used as
hosts for the in vivomodel. The experiments on animals were approved
by the ethical committee of the Catholic University School of Medi-
cine, Rome, Italy. For subcutaneous grafting, either 1 × 106 TB10
GBM cells [23] or 5 × 105 BTSC83 GBM stem cells [19,24] were
harvested, washed twice, and resuspended in cold PBS. Then, 100 μl
of cells were mixed with 100 μl of Matrigel (BD Bioscience) on ice, and
the mixture was implanted by subcutaneous injection using a 25-gauge
needle.Only one injection was performed on a singlemouse. After graft-
ing, mice were kept under pathogen-free conditions in positive-pressure
cabinets (Tecniplast Gazzada, Varese, Italy) and observed weekly for
appearance of subcutaneous nodules at injection site. Mice were killed
with an overdose of barbiturate either 12 weeks after injection or when
the subcutaneous nodules reached 15 mm in maximum diameter. The
subcutaneous tumor was removed, fixed in 4% paraformaldehyde,
embedded into paraffin, cut in 5-μm-thick sections, and stained with
hematoxylin and eosin. Immunohistochemical analysis was performed
as above.
Statistical Methods
Differences in TfR2 expression among LGA, AA, and GBM groups
were evaluated using the χ 2 test. In GBM tumors, the relationship
between the level of TfR2 staining and overall patients’ survival was eval-
uated by using Pearson’s correlation coefficient. The coefficient was ana-
lyzed by a t test. Statistical significance was assigned to P < .05. The
computer software used for statistical analysis was Fig. P (Biosoft,
Cambridge, UK).
Results
TfR2 Expression in GBM Cell Lines
We investigated TfR2 expression in four GBM cell lines (TB10,
U87MG, T98G, and U251), showing that TB10 and U251 strongly
express TfR2, as assessed both by flow cytometry and by Western blot
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analysis (Figure 1, A and B). Interestingly, the TB10 GBM cell line ex-
presses TfR2 but not TfR1 (CD71; Figure 1, A and B).
We also evaluated TfR2 expression in two human GBM stem cell
lines (BTSC1 and BTSC83), which have been established in our labo-
ratory from dissociation of tumor spheres under stem cell culturing con-
ditions [19,24]. The experiment showed that TfR2 is highly expressed
in BTSC83 cell line (Figure 1, A and B).
TfR2 Localization in Lipid Rafts
In a previous study, we showed that TfR2 is localized in lipid rafts
in erythroleukemic K562 and hepatoma HepG2 cells [7]. Therefore,
it seemed important to evaluate TfR2 localization in GBM cells. A
sucrose density gradient ultracentrifugation of cell lysates was used to
purify lipid raft microdomains. After sucrose gradient centrifugation,
detergent-resistant lipid rafts float to low-density fractions because of
their high lipid content. These insoluble membranes, visible as a white
opalescent band in fraction numbers 4, 5, 6, and 7, were compared
with soluble fraction numbers 8, 9, 10, and 11 for TfR2 content.
Immunoblot analysis performed on SDS-PAGE loaded with equal
amount of protein for each fraction showed that TfR2 was predomi-
nantly located in insoluble fractions in both TB10 and U251 cells.
Caveolin-1, which was used to track the position of caveolae-enriched
membranes, was detected in insoluble fractions (Figure 1, C andD). As
expected, in U251 cells, the nonraft marker TfR1 was localized in
soluble fractions 9 to 11 (Figure 1D).
To confirm the immunoblot data concerning the plasma membrane
sublocation of TfR2, we performed immunofluorescence double stain-
ing to localize TfR2 and the raft-resident cav-1 protein. In both TB10
and U251 cells, TfR2 and cav-1 largely colocalized in the plasma mem-
brane (Figure 2).
TfR2 Activates ERK1/ERK2 Phosphorylation
Given that sucrose gradient centrifugation experiments provided
some evidence that TfR2 was localized at the level of lipids rafts and that
these microdomains play an important role in signal transduction [25],
it seemed logical to evaluate whether triggering this receptor may acti-
vate signal transduction. Because mitogen-activated protein kinase
(MAPK) activation was proved to be crucial in signal transduction of
a large number of membrane receptors and ERK1/ERK2 have been
shown to be phosphorylated after TfR2 activation in K562 cells [7],
we investigated whether TfR2 stimulation might lead to the activation
of this pathway in GBM cells. To address this point, we performed
stimulation of serum-starved TB10 or U251 cells with human Tf. The
results of this experiment showed that exposure of TB10 cells in the
presence holo-Tf 30 μM resulted in a marked phosphorylation of
ERK1/ERK2 (Figure 3A). Because TB10 cells possess only TfR2 and
completely lack TfR1, the stimulatory effect of holo-Tf on ERK1/
ERK2 phosphorylation could be related only to TfR2 activation. In
parallel, we showed that TfR2 cross-linking with the anti-TfR2 mAb
G/14C2 (data not shown) and treatment with apo-Tf (Figure 3A) led
to ERK1/ERK2 activation. To further demonstrate that the stimulatory
effect of holo-Tf is related toTfR2 and not to TfR1, serum-starvedTfR2−
U87MG cells have been treated for the indicated times with holo-Tf
30 μM, showing no phosphorylation of ERK1/ERK2 (Figure 3A).
In parallel, we have evaluated the capacity of specificMEK1 inhibitors,
such as PD184352, to inhibit the growth of TB10 cells. This experiment
showed that PD184352 potently inhibited in a dose-dependent manner
Figure 1. TfR2 expression in GBM cell lines. (A) Flow cytometry analysis of TfR1 and TfR2 expression in TB10, U87MG, T89G, and U251
GBMcell lines and in BTSC1 and BTSC83 GBM stem cell lines. Cells have been labeledwith anti-TfR1 and anti-TfR2mAbs and then analyzed
by flow cytometry. (B)Western blot analysis of TfR1 and TfR2 expression in TB10, U87GM, T98G, and U251 GBMcell lines and in BTSC1 and
BTSC83 GBM stem cell lines. Blots were stripped and reprobed for actin to ensure equivalent loading and transfer. (C and D) Association of
TfR2 with lipid rafts/caveolae by density gradient centrifugation. TB10 (C) and U251 (D) cells were lysed in Triton X-100 and subjected to
sucrose gradient centrifugation. Aliquots of fractions collected from the top of the gradient were analyzed byWestern blot analysis with the
use of antibodies against TfR1, TfR2, and caveolin-1 (Cav-1). Equal protein amounts for each fraction were loaded on SDS-PAGE.
126 Transferrin Receptor 2 in Glioblastoma Calzolari et al. Translational Oncology Vol. 3, No. 2, 2010
the growth of TB10 cells (Figure 3B). Similar results have been obtained
in TfR2−GBMcells (data not shown), suggesting that theMAPK path-
way contributes to cellular proliferation of GBM cells, regardless of
TfR2 expression.
Hypoxia Upmodulates TfR2 Expression
Previous studies have shown that hypoxia is an important modulator
of TfR1 expression [26,27]. Conversely, hypoxia regulates the neo-
angiogenetic mechanisms that are particularly active in GBM [28].
Therefore, it seemed important to evaluate a possible effect of hypoxia
on TfR2 modulation in GBM cell lines. To this end, we grew TB10
and U251 cells in the presence of 100 μMCoCl2, an agent mimicking
hypoxia, or under reduced oxygen tension (5% and 1% O2) and we
measured the level of TfR2 expression both by flow cytometry and
byWestern blot analysis. As expected, CoCl2 treatment and low oxygen
tension (1% O2) induced a marked rise of HIF-1α levels (Figure 4B).
Then, CoCl2 treatment elicited a significant TfR2 upmodulation that
was quite remarkable in TB10 cells (Figure 4, A, B, and D). Similarly,
TfR2 expression was upmodulated under hypoxic conditions, com-
pared with normal oxygen tension (20% O2), especially in TB10 cells.
Figure 3. TfR2 stimulation activates ERK1/ERK2 MAPK. (A) Activation of ERK1/ERK2 MAPK. TB10 (left panel) and U87MG (middle panel)
cells were serum-starved, treated with 30 μM human holo-Tf for the indicated times and subjected to immunoblot analysis with anti–
phospho-ERK1/ERK2. Blots were stripped and reprobed for total ERK1/ERK2 and for TfR2 to ensure equivalent loading and transfer.
U251 cells (right panel) were serum-starved, treated with the stimulation medium in the absence (NT indicates not treated) or in the
presence of 30 μM human holo-Tf and 30 μM human apo-Tf for 30 minutes at 37°C and subjected to immunoblot analysis with anti–
phospho-ERK1/ERK2. (B) Effect of ERK1/ERK2 phosphorylation inhibitor on the growth of TB10 cells. TB10 cells have been grown either
in the absence or in the presence of the MEK-1 inhibitor PD184352, added either at 1 or 2 μM.
Figure 2. Association between TfR2 and caveolin-1 in lipid rafts as shown by immunofluorescence experiments. TB10 and U251 cells were
plated on glass coverslips and left to adhere overnight. TfR-2 was visualized by incubating cells with anti–TfR_2 mAb and then with Texas
Red–conjugated antimouse IgG (red fluorescence). Cells were then fixed, permeabilized, and then labeled with caveolin-1 antibody followed
by Alexa 488–conjugated antirabbit antibody (green fluorescence). An image of a representative cells is shown reporting the red (TfR-2),
green (Cav-1), merged fluorescence (at two different magnifications), and phase contrast.
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TfR2 Expression in Astrocytic Tumors
Using specific mAbs antihuman TfR2, whose specificity had previ-
ously been reported [18], we assessed by immunohistochemistry (IHC)
the expression ofTfR2 in 81 astrocytic tumors, 24LGAs (WHOgrade 2),
22 AA (WHO grade 3), and 35 GBM (WHO grade 4). The intensity
of IHC staining for TfR2 in the tumor cells was graded on a scale
ranging from 0 to 3+: 0, no detectable staining; 1+, slight cytoplasmic
staining discernible only in a 400× high-power field; 2+, moderate
cytoplasmic staining clearly detectable in a 100 to 200× field; and 3+,
intense cytoplasmic staining detectable in a 20× field, obscuring cellular
details. We also assessed the percentage of TfR2-positive cells relative
to the total number of tumor cells.
Results of IHC analysis are presented in Figure 5. Overall, the level
of TfR2 expression by the tumor cells was related to histologic grade.
Staining for TfR2 was scored 0 to 1+ in 22 (91.7%) of 24 LGA, 6
(27.3%) of 22 AA, and 14 (40%) of 35 GBM tumors (Figure 5A).
Of 22 cases classified as showing 2+ staining, there were 1 (4.2%) of
24 LGA, 11 (50%) of 22 AA, and 10 (28.6%) of 35 GBM. The highest
degree of TfR2 expression (3+) was detected in 1 (4.2%) of 24 LGA, 5
(21.7%) of 22 AA, and 11 (31.4%) of 35 GBM (Figure 5A; P < .05,
χ 2 test). Regarding distribution of TfR2 staining, of 35 GBM, 28 (80%)
showed TfR2-positive immunoreaction in more than 50% of the
tumor cells, 5 (14.3%) contained 25% to 50% TfR2-positive cells,
and 2 (5.7%) had no TfR2-positive cells. Among 22 AA, 2 (9%),
10 (45.5%), 9 (41%), and 1 (4.5%) tumors showed TfR2 expression
by more than 50% of cells, by 25% to 50% of cells, by less than 25%
of cells, and by 0% of cells, respectively. Finally, of 24 LGA, 2 (8.4%)
showed 25% to 50% TfR2-positive cells, 12 (50%) had less than
25% TfR2-positive cells, and 10 (41.6%) were completely devoid
of TfR2-positive cells.
Figure 4. Effect of hypoxia on TfR2 expression. (A) Flow cytometry analysis of TfR2 expression in TB10 cells grown for 40 hours either in the
absence (C) or in the presence of 100 μMCoCl2. (B) Western blot analysis of HIF-1α expression in U251 cells grown for either 24 or 48 hours
either in the absence (C) or in the presence of 100 μMCoCl2 and in TB10 cells grown for 48 hours under normal (20%O2) and reduced (5%
and 1% O2) oxygen tension. (C) Analysis of the level of fluorescence (mean fluorescence intensity values normalized with respect to their
negative control) of TfR2 labeling observed in TB10 and U251 cells grown for either 24 or 48 hours either in the absence (C) or in the pres-
ence of 100 μMCoCl2 or under controlled (20%, 5%, and 1%O2) oxygen tension. Data represent the mean values ± SEM observed in three
independent experiments. *P< .05, **P< .01. NS indicates not significant. (D) Western blot analysis of TfR2 expression in U251 and TB10
cells grown for 24 or 48 hours either in the absence (C) or in the presence of 100 μMCoCl2 or under controlled (20%, 5%, and 1%O2) oxygen
tension. (E) TfR2 levels in TB10 and U251 cells grown under controlled (20%, 5%, and 1% O2) oxygen tension have been determined by
densitometry of Western blot autoradiograms and, after normalization with respect to actin, have been expressed in arbitrary units (AU) and
then plotted.
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In GBM tumors, a highly significant correlation was noted between
the expression level of TfR2 and overall patients’ survival (P < .0001,
Pearson linear correlation coefficient), demonstrating that higher levels
of TfR2 expression were significantly associated with a better prognosis
(Figure 5B). A similar relationship, although at a lower level of signifi-
cance, was also found when the overall patients’ survival was plotted
against the percentage of TfR2-positive cells in the tumor tissue (P =
.037, Pearson linear correlation coefficient; Figure 5C ). Representative
examples of TfR2 IHC staining are shown in Figure 5D.
It was worthy noting that 21 (60%) of 35GBMcases scoring 2+ to 3+
showed a prominent staining for TfR2 in the endothelial cells of arteri-
oles and capillaries of the tumor vasculature (Figure 5E). In contrast,
TfR2 staining was not detected in the vessels of normal brain as well
as in the tumor vessels of LGA.
GBM Cell Lines Sensitivity to Temozolomide
Because patients with GBMs expressing higher levels of TfR2 survive
longer than patients with low-expressing TfR2 GBMs, it seemed of
Figure 5. TfR2 expression in astrocytic tumors. (A) Degree of TfR2 expression in 81 astrocytic tumors differing in histologic grade. (B and C)
Graphs showing the relationship between overall patients’ survival and either the degree of TfR2 immunostaining (B) or the percentage of
TfR2-positive cells (C) in 35 GBM tumors. The variables were significantly related with a 95% confidence interval (P< .0001 and P< .05 in B
and C, respectively; Pearson linear correlation coefficient). (D) Immunohistochemical analysis of TfR2-negative (0) LGA, AA scoring 1+ TfR2
expression, GBM showing 2+ TfR2 expression and GBM showing 3+ TfR2 expression. Bar, 75 μm. (E) Anti-TfR2 IHC of blood vessels in a
GBM tumor showing immunoreactive endothelial cells (arrows, left panel) and in a normal brain specimen with negative endothelial cells
(arrow, right panel). Bar, 35 μm.
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interest to compare the in vitro sensitivity to temozolomide of TfR2+
and TfR2− GBM cell lines. To do these experiments, either the TfR2+
TB10 and U251 cell lines or the TfR2− U87MG and T98G cell lines
were grown in vitro in the presence of increasing concentrations of
temozolomide (from 25 to 300 μM). The results of these experiments
were evaluated in terms of the number of living cells and showed that
temozolomide exerted a more pronounced inhibitory effect on the
growth of TfR2+ than TfR2- cell lines (Figure 6A, left panel ). The in-
hibitory effect of temozolomide on GBM cell proliferation was related
to a blockade of these cells in G2/M phase of the cell cycle, and this
effect was more pronounced in TfR2+ than in TfR2− cells (Figure 6A,
right panel ).
To investigate whether temozolomide sensitivity of GBM cells was
directly related to TfR2 expression in these cells, we have evaluated
the effect of TfR2 silencing on temozolomide sensitivity. U251 cells
were transfected either with a specific TfR2 siRNA or with a negative
control siRNA and then treated for 72 hours with 300 μM temozolo-
mide. The results have shown that TfR2 siRNA treatment of U251 cells
does not affect the inhibitory effect of temozolomide on cellular prolif-
eration, as demonstrated by the analysis of the number of living cells
(Figure 6B, left panel ) and of the percentage of cells in the G2/M phase
of cell cycle (Figure 6B, right panel ). These experiments clearly demon-
strate that the higher sensitivity to temozolomide of TfR2+ cells com-
pared with TfR2− cells is associated to, but not directly dependent on,
TfR2 expression.
TfR2 Silencing Reduces GBM Cell Growth
To evaluate a possible effect of TfR2 on the proliferation of GBM
cells, TfR2+ GBM cell lines were transfected either with a specific
TfR2 siRNA or with a negative control siRNA. The TfR2 protein
was knocked down inTB10 andU251 cells by five- to six-fold (Figure 7,
A and B). There was no significant difference in TfR2 expression
between cells transfected with negative control siRNA and those trans-
fected with vehicle alone (Figure 7, A and B). TfR1 expression was not
affected by TfR2 siRNA transfection (Figure 7A). Treatment of cells
with TfR2 siRNA resulted in significantly reduced cell proliferation,
compared with control values (Figure 7C ). The presence of TfR1 in
U251 cells may explain the lower effect of TfR2 silencing on the growth
of U251 compared with TfR1− TB10 cells.
TfR2 Expression in GBM Xenografts
For the in vivo experiments, we used two GBM cell lines that had
been established in our laboratory [23,24]. The TB10 cell line has been
shown both to generate tumor xenografts in nude mice and to express
TfR2under in vitro conditions [8,29]. Therefore, this cell linewas suited
to assess whether TfR2 expression is maintained in in vivo conditions.
The second GBM cell line (BTSC83), which has been established
from dissociation of tumor spheres under stem cell culturing conditions
[19,24], would answer the question whether TfR2 is expressed by
the subpopulation ofGBMcells with properties of cancer initiating cells.
IHC revealed that the tumor xenografts generated both by TB10 and by
Figure 6. Effect of temozolomide on cell proliferation and cell cycle. (A) Cell lines TB10, U251, T98G, and U87MG were treated with control
medium (C) or temozolomide (TMZ) at the indicated concentrations and then trypsinized and counted after 72 hours of incubation at 37°C
(left panel). The cells were subjected to cell cycle analysis in flow cytometry. Data shown are percentages of the cells in the G2/M phase
(right panel). (B) U251 cells were transfected with control siRNA (40 nM) or TfR2 siRNA (60 nM), treated for 72 hours with temozolomide
300 μM, and then analyzed for the number of living cells (left panel) and the percentage of the cells in G2/M phase (right panel).
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BTSC83GBMcells do express TfR2 (Figure 8). TfR2 immunoreaction
selectively stained the neuroepithelial cells of the tumor xenografts,
whereas the stromal component of the xenografts was TfR2-negative.
In line with the positivity of endothelial cells of arterioles and capil-
laries of primary tumors, we observed also a clear TfR2 positivity at the
level of the neoformed blood vessels of GBM xenografts (Figure 9).
Discussion
Glioblastoma multiforme is the most common and aggressive primary
malignant brain tumor in adults. Despite improvements in overall sur-
vival with the addition of temozolomide to radiation in the adjuvant
setting, the prognosis of patients affected by these tumors remains very
poor. For these reasons, there is an absolute need for the development
Figure 7. Inhibition of TfR2 expression by siRNA treatment reduces GBM cell growth. (A) Western blot analysis of TfR1 and TfR2 expres-
sion in U251 cells transfected with TfR2 siRNA or nontargeting control siRNA (CsiRNA), compared with untreated (C) cells. (B) Flow cyto-
metry analysis of TfR2 expression in U251 and TB10 cells transfected with TfR2 siRNA or CsiRNA. Data represent the mean values ± SEM
observed in three independent experiments (*P < .05, **P < .01; NS indicates not significant). (C) After treatment with TfR2, siRNA or
CsiRNA U251 and TB10 cells have been analyzed for the number of living cells. Data represent the mean values ± SEM observed in three
independent experiments (*P < .05, **P < .01).
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of innovative therapies. Among them, targeted therapy seems to be
particularly challenging. These therapies may target either intracellular
signaling pathways (i.e., mammalian target of rapamycin, protein ki-
nase C) or membrane growth factor receptors (i.e., epidermal growth
factor receptor or vascular endothelial growth factor receptor). Alterna-
tively, target therapies may be based on the identification of membrane
molecules expressed on the surface of glioma cells and not on their nor-
mal counterpart.
In this report, we provide evidence for the first time that TfR2 repre-
sents a membrane antigen abundantly expressed on malignant glioma
cells but not expressed on neural cells as well as on endothelial cells of
normal brain. The absence of TfR2 expression in normal brain recently
reported by a study showing the absence of TfR2 mRNA in normal
human brain, with the exception of cerebellum [30]. In this same study,
preliminary evidence about the frequent expression of TfR2 mRNA in
human brain tumors, including oligodendroglioma, oligoastrocytoma,
and astrocytoma was provided [30]. Our immunohistologic analysis
on 81 astrocytic tumors of various histologic grades clearly shows that
TfR2 expression is related with malignancy. This finding suggests that
the induction of TfR2 in malignant glioma cells may provide a growth
advantage to these cells. In linewith this interpretation, we observed that
in GBM cell lines TfR2 activation induces a rapid and pronounced
ERK1/ERK2 phosphorylation. Previous studies have shown that
ERK1/ERK2 is constitutively activated in human GBM [31–33] and
that the level of ERK1/ERK2 activation represents a negative prognostic
factor. In line with this interpretation, we observed that in GBM cells
TfR2 appears to be localized at the level of lipid rafts, which are thought
to act as molecular sorting mechanisms, capable of coordinating the
organization of signal transduction pathways within limited regions of
the plasma membrane and organelles [25].
Figure 8. TfR2 expression in GBM xenografts. Tumor xenografts were obtained by subcutaneous injection of either TB10 or BTSC83 human
GBM cell lines in nude athymic mice. The tumor xenografts obtained both with TB10 cells and with BTSC83 cells show an intense expres-
sion of TfR2 by the tumor cells. Bar, 50 μm.
Figure 9. TfR2 expression by the neoformed blood vessels of GBM
xenografts. TfR2-positive cells lining the lumen of vascular struc-
tures both in TB10 (arrows, upper panel) and in BTSC83 tumor xeno-
grafts (arrows, lower panel). Bar, 35 μm.
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Consistent with this notion, it is tempting to hypothesize that TfR2,
which is expressed at high levels on GBM cells, may be constitutively
activated by plasmatic holo-Tf. In line with this hypothesis, silencing
experiments of TfR2 using TfR2 siRNA showed that TfR2 expres-
sion contributes to in vitro proliferation of GBM cells. Thus, TfR2
may be continuously involved in ERK1/ERK2 activation, conveying a
proliferative/survival signal to cancer cells. Accordingly, previous studies
have shown that Ras is very rarely mutated in GBM, suggesting that
MAPK-dependent mitogenic signaling in GBM is triggered through
inappropriate activation of membrane receptors [34].
We have also observed that the level of TfR2 expression on GBM
tumors represents a positive prognostic factor. In fact, patients with high
TfR2 expression on their tumor cells survive longer than patients with
low TfR2 expression. Because the treatment plan of these patients in-
cluded radiotherapy and temozolomide [35], we investigated whether
GBMcell lines displayed in vitro differential sensitivity to temozolomide
relative to their TfR2 expression levels. Our results show that TfR2+
GBM cell lines are more sensitive to temozolomide than TfR2− GBM
cell lines. The higher sensitivity of TfR2+ GBM cell lines seems to be
associated to TfR2 positivity, but not directly dependent on it, as shown
by temozolomide treatment of TfR2 knock down cells. The ensemble
of these observations suggests that the expression of TfR2 on GBM
tumor cells is associated with a higher sensitivity to the antiproliferative
effects of temozolomide andmay explain the better prognosis of patients
harboring TfR2+ GBM. The finding that the higher sensitivity to temo-
zolomide of TfR2+ cells is associated but not directly linked to TfR2
positivity of the tumor may help to explain why intriguingly TfR2
expression increases with tumor grade but is inversely correlated to
patients’ survival.
The molecular mechanisms responsible for the induction of TfR2
expression in malignant glioma cells are, at the moment, completely
unknown. In normal tissues, TfR2 is expressed only in liver cells and,
at lower levels, in epithelial intestinal cells [36]. The mechanisms re-
sponsible for the regulation of TfR2 expression at tissue level are also
unknown. However, in this context, it is of interest to note that TfR2
gene is located on chromosome 7 at the 7q22 region [5], and this
chromosome is very frequently (>75% of cases) involved in numeric
chromosomal abnormalities (trisomy/polysomy 7) [37]. Previous stud-
ies have shown that various stimuli, including iron levels, nitric oxide,
and hypoxia, are able to modulate TfR1 expression in various normal
andmalignant cells [26,27]. Among these stimuli, it seemed particularly
important to evaluate any possible effect of hypoxia on TfR2 expression
in GBM cells. It is known that malignant gliomas are among the most
vascular of all solid tumors and that hypoxia-dependent pathways are
largely involved in the neoangiogenetic mechanisms operating in these
tumors [28,38,39]. Particularly, it seemed important to demonstrate
that a high TfR2 expression can be maintained even under conditions
of hypoxia, which are frequently observed in growing GBM. Our ex-
periments on GBM cell lines showed that CoCl2 and reduced oxygen
tension are able to induce an increase of TfR2 expression.
Amajor finding of our study is that TfR2 is expressed by the stem cell
compartment of GBM and that the tumor xenografts generated both
by GBM cell lines and by GBM stem cells retain TfR2 expression
in vivo. These results are of particular interest to design preclinical mod-
els of target therapy. In this respect, two features of TfR2 expression on
GBM cells seem very suitable for the development of targeted therapy
using an immunotoxin based on an anti-TfR2 mAb: 1) TfR2 is clearly
expressed on almost all cases of AA andGBMand 2) inmost cases, TfR2
is expressed virtually on all tumor cells. Furthermore, the expression
pattern of TfR2 seems much more suitable for immunotherapy than
that of TfR1. In fact, TfR1 is expressed not only on GBM cells but also
on the endothelial cells of the normal brain, whereas TfR2 is expressed
only by the tumor cells and not by the normal brain tissue. Pilot clinical
trials based on the use of Tf-CRM107, a molecule acting through bind-
ing to TfR1, have shown that this conjugate does exert a strong anti-
tumor cytotoxicity and that it also induces a significant peritumoral
toxicity owing to thrombosis of cortical vessels [16]. This limiting peri-
tumoral toxicity is not expected using anti-TfR2 immunoconjugates
because TfR2 is not expressed on normal brain endothelial cells.
It is of interest to note that we recently described the expression of
TfR2 in colon carcinomas (26% of colon carcinomas were TfR2+,
whereas normal colon mucosa was TfR−) [40]. This observation,
together with the findings of the present study, indicates that TfR2 is
a membrane receptor whose expression in normal tissues is restricted to
hepatic cells while it is frequently expressed in tumor cells.
In conclusion, the present study demonstrates for the first time that
TfR2 is a tumor neoantigen for human malignant gliomas and that it
meets many of the requirements needed to develop target therapies.
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